ADRB2 and neoplasm: Retrospective analyses of patient data have also revealed a strong correlation between reduced tumor progression, metastasis, and mortality, and the use of β-AR antagonists in breast, ovarian, and prostate cancer patients, as well as melanoma patients [15, 49-58].